The Study
Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition.
This study looked at rats and lab-grown heart cells, not people. It saw that a medicine called dapagliflozin seemed to help the heart cells and scar tissue behave better — but we don’t know if it would do the same in humans.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
A medicine called dapagliflozin, used for diabetes, was tested in rats with heart attacks. It helped their hearts work better and live longer by calming down scar-making cells and protecting heart muscle cells from stress.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 56 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The results suggest this drug might help human hearts recover after heart attacks, but it hasn't been tested in people yet.
- 2In rats: survival improved, heart function got better, scar proteins went down, stress chemicals dropped, and inflammation decreased.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Life sciences
Year
2025
Authors
Min Xu, Yanjing Feng, Xin Xing, Miao Yuan, Guantong Fang, Botao Wu, Linwan Zhang, Dengfeng Gao
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.